Affinage

FABP1

Fatty acid-binding protein, liver · UniProt P07148

Length
127 aa
Mass
14.2 kDa
Annotated
2026-06-09
100 papers in source corpus 34 papers cited in narrative 34 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 6/6 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

FABP1 (L-FABP) is a cytosolic lipid-binding chaperone that governs intracellular uptake, trafficking, and metabolic targeting of long-chain fatty acids and other lipophilic ligands in liver and intestine, coupling cytoplasmic lipid handling to nuclear transcriptional control of fatty-acid oxidation (PMID:9688651, PMID:23238934). Beyond facilitating cellular fatty-acid and cholesterol uptake and intracellular diffusion (PMID:9688651, PMID:8232270, PMID:28919479), FABP1 binds PPARα directly with high affinity and at close intermolecular distance, and redistributes to the nucleus upon stimulation by polyunsaturated fatty acids or fibrate ligands to deliver activating ligands to PPARα, shifting its coactivator/corepressor balance toward SRC-1 and driving expression of β-oxidative enzymes such as CPT1A, CPT2, and ACOX1 (PMID:19289416, PMID:19285478, PMID:23238934, PMID:23747828); this nuclear signaling is genetically dependent on both L-FABP and PPARα, whereas ATGL-driven channeling of fatty acids to oxidation proceeds independently of L-FABP (PMID:23238934, PMID:24610891). The protein also localizes to the peroxisomal matrix and stimulates peroxisomal β-oxidation and acyl-CoA thioesterase activity (PMID:16262600). FABP1 broadens to non-fatty-acid ligands, serving as the major hepatic endocannabinoid binding/transport protein that controls hepatic AEA and 2-AG levels and modulates their hydrolysis by MAGL/FAAH (PMID:27552286, PMID:30203570), and as a hepatic Δ9-THC transport protein that accommodates THC in its binding pocket and is required for cannabinoid biotransformation and inactivation (PMID:31110286, PMID:30232874). FABP1 additionally regulates hepatic bile acid pool size and biliary cholesterol metabolism (PMID:15984932, PMID:25277800), buffers oxidative stress by sequestering free fatty acids (PMID:23359610), and is itself subject to oxidative modification by 4-HNE, transcriptional control by FOXA1/PPARα/HNF4α and C/EBPα, post-transcriptional regulation by DDX5, stabilization by AGR2, and Derlin-1/Trim25-mediated ubiquitin-proteasomal degradation (PMID:22701647, PMID:23318274, PMID:37499886, PMID:33767592, PMID:32817263). The human T94A coding variant is an altered-function allele that reshapes the structural response to fatty-acid binding, blunts fibrate/PUFA-driven PPARα activation, and increases cholesterol binding and hepatic lipid accumulation (PMID:24628888, PMID:25732850, PMID:24875102).

Mechanistic history

Synthesis pass · year-by-year structured walk · 20 steps
  1. 1993 Medium

    Established that cytosolic L-FABP levels causally control the magnitude and specificity of cellular lipid uptake, defining its core function as a facilitator of fatty-acid and cholesterol absorption.

    Evidence Stable L-FABP transfection of L-cell fibroblasts with fluorescent lipid uptake and ACAT activity assays

    PMID:8232270

    Open questions at the time
    • Single overexpression system, not loss-of-function
    • Did not resolve whether trafficking is directed or diffusional
  2. 1998 Medium

    Distinguished uptake from intracellular transport, showing L-FABP accelerates both membrane fatty-acid uptake and cytoplasmic diffusion of internalized fatty acid.

    Evidence Fluorescence digital imaging of NBD-stearate in L-FABP-transfected L-cells

    PMID:9688651

    Open questions at the time
    • Heterologous fibroblast context, not native hepatocyte
    • No nuclear targeting addressed
  3. 2005 High

    Demonstrated physiological roles beyond passive transport: L-FABP regulates hepatic bile acid pool size and biliary cholesterol metabolism, and circulating L-FABP is reabsorbed in kidney via megalin-mediated endocytosis.

    Evidence L-FABP knockout mice with bile acid quantification; in vivo renal uptake plus quartz-crystal microbalance megalin binding and cell degradation assays

    PMID:15696188 PMID:15984932

    Open questions at the time
    • Bile acid phenotype is indirect, mechanism of transporter/enzyme changes not resolved
    • Renal handling does not establish a renal physiological function
  4. 2005 Medium

    Identified a cytoprotective antioxidant function, linking lipid sequestration to reduced oxidative damage.

    Evidence L-FABP-transfected Chang liver cells with ROS and LDH-release assays under oxidative stress

    PMID:16175609

    Open questions at the time
    • Mechanism (direct vs indirect via FA sequestration) not distinguished in this study
    • Single overexpression cell model
  5. 2006 High

    Revealed dual subcellular localization with function, placing a soluble pool of L-FABP in the peroxisomal matrix where it stimulates β-oxidation.

    Evidence Subcellular fractionation, 2D-gel/MS, immunoelectron microscopy, and in vitro peroxisomal β-oxidation assays

    PMID:16262600

    Open questions at the time
    • Import mechanism into peroxisomes unresolved
    • Quantitative contribution of peroxisomal pool to total flux unclear
  6. 2007 Medium

    Showed L-FABP is exploited as a host factor for malaria liver-stage development via interaction with parasite protein UIS3.

    Evidence Yeast two-hybrid screen plus L-FABP knockdown/overexpression in hepatocytes with parasite growth readout

    PMID:17303141

    Open questions at the time
    • Interaction not validated by mammalian-cell reciprocal Co-IP
    • Lipid-delivery basis of the host dependence not defined
  7. 2009 High

    Provided the central mechanistic link of the field: L-FABP binds PPARα directly and delivers fatty-acid ligands to the nucleus, converting cytosolic lipid sensing into PPARα transcriptional activation.

    Evidence Co-IP of pure proteins, in vitro and confocal FRET, CD, immunogold EM; plus KO hepatocyte imaging, reciprocal coactivator/corepressor Co-IP, and oxidation assays

    PMID:19285478 PMID:19289416

    Open questions at the time
    • Structural interface of the FABP1-PPARα complex not solved
    • Mechanism of ligand handoff and FABP1 nuclear import not defined
  8. 2012 Medium

    Defined ligand-dependent oxidative regulation: 4-HNE adducts specific residues to impair binding and stability, and L-FABP loss sensitizes liver to ethanol-induced lipid peroxidation, establishing an indirect antioxidant role.

    Evidence MALDI-TOF/TOF residue mapping with binding/thermal-stability assays; and ethanol-fed L-FABP KO mice with oxidative-stress markers

    PMID:22701647 PMID:23359610

    Open questions at the time
    • In vivo significance of specific 4-HNE adduct sites untested
    • Antioxidant role inferred from FA sequestration, not directly measured
  9. 2012 High

    Demonstrated genetic epistasis: PUFA- and fibrate-driven induction of PPARα β-oxidative target genes requires both L-FABP and PPARα, and L-FABP nuclear redistribution is ligand-triggered and glucose-potentiated.

    Evidence Primary hepatocytes from WT, L-FABP-null and PPARα-null mice with transcription assays, real-time confocal imaging, Co-IP, and oxidation assays

    PMID:23238934 PMID:23747828

    Open questions at the time
    • Signal that triggers nuclear redistribution not identified
    • Glucose-potentiation mechanism unresolved
  10. 2013 Medium

    Mapped the transcriptional and cellular regulation of FABP1, identifying FOXA1/PPARα/HNF4α as activators and C/EBPα as a repressor, and a role in hepatic stellate cell lipid storage and activation.

    Evidence Promoter reporter/mutagenesis and TF overexpression/silencing in HepG2 and primary hepatocytes; plus L-FABP KO/adenoviral-rescue primary HSC studies

    PMID:23318274 PMID:23401290

    Open questions at the time
    • Promoter findings from cell lines may not capture in vivo regulation
    • HSC role does not establish direct fibrogenic mechanism
  11. 2014 High

    Resolved the functional consequences of the human T94A variant and bounded the pathway, showing T94A blunts PPARα signaling and shifts lipid partitioning while ATGL-driven oxidation is L-FABP-independent.

    Evidence Recombinant T94A biochemistry with CD; genotyped primary human hepatocyte functional assays; and ATGL knockdown/overexpression in WT and L-FABP KO mice

    PMID:20721681 PMID:24610891 PMID:24628888 PMID:24875102

    Open questions at the time
    • Clinical phenotype attribution to T94A not established here
    • Structural basis of altered binding response only modeled
  12. 2015 High

    Identified enhanced cholesterol binding as a distinct gain-of-function property of the T94A variant.

    Evidence NBD-cholesterol fluorescence and ITC binding assays plus genotyped human hepatocyte cholesterol-uptake assays

    PMID:25732850

    Open questions at the time
    • In vivo cholesterol-handling consequence not tested
    • Relationship to fatty-acid binding pocket changes not integrated
  13. 2016 High

    Expanded the ligand repertoire to endocannabinoids and identified FABP1 as the major hepatic endocannabinoid transport protein controlling AEA/2-AG levels.

    Evidence In vitro binding/displacement assays plus LC-MS endocannabinoid quantification in FABP1-KO vs WT liver

    PMID:27552286

    Open questions at the time
    • Downstream cannabinoid-receptor signaling consequences not addressed
    • Tissue-specificity of EC control beyond liver unknown
  14. 2018 High

    Refined endocannabinoid handling, showing distinct binding stoichiometries and that FABP1 enhances MAGL-mediated 2-AG hydrolysis while differentially affecting AEA versus 2-AG uptake.

    Evidence In vitro MAGL/FAAH hydrolysis and binding assays with recombinant FABP1, plus KO hepatocyte LC-MS and real-time imaging

    PMID:30203570

    Open questions at the time
    • Physical FABP1-MAGL interaction not demonstrated
    • Structural basis of distinct binding sites not resolved
  15. 2019 High

    Established FABP1 as a hepatic cannabinoid (THC) transport protein required for biotransformation, with a solved THC-bound structure and behavioral consequences of loss.

    Evidence X-ray crystallography, in vitro binding, FABP1-KO primary hepatocyte THC metabolism, and KO mouse PK/PD with behavioral readout; plus prior THC-metabolite binding and KO transcriptional studies

    PMID:30232874 PMID:31110286

    Open questions at the time
    • Mechanism linking FABP1 binding to CYP-mediated metabolism not yet defined
    • Whether FABP1 directly contacts metabolizing enzymes unknown
  16. 2019 Medium

    Linked FABP1 abundance to autophagy, showing hepatic overexpression inhibits autophagic flux and lysosomal function to promote steatosis.

    Evidence Adenoviral liver-specific FABP1 overexpression in mice with autophagic-flux, lysosomal-function, and proteomic assays

    PMID:31366243

    Open questions at the time
    • Molecular mechanism of lysosomal inhibition unresolved
    • Loss-of-function confirmation lacking
  17. 2021 Medium

    Identified post-translational stabilization of FABP1 by AGR2 via a disulfide-dependent interaction required for lipid accumulation.

    Evidence Co-IP, AGR2 PDI-motif mutagenesis rescue, FABP1 stability assays, and KO/overexpression mouse models

    PMID:33767592

    Open questions at the time
    • Single-lab Co-IP without reciprocal cross-lab validation
    • Stoichiometry and subcellular site of complex unclear
  18. 2023 Medium

    Defined a degradation pathway, with Derlin-1 recruiting Trim25 to ubiquitylate FABP1 for proteasomal turnover and limit lipid deposition.

    Evidence Co-IP/MS, ubiquitination assays, and adenoviral Derlin-1 overexpression in mice and HepG2 cells

    PMID:37499886

    Open questions at the time
    • Trim25 ubiquitylation site on FABP1 not mapped
    • Signal triggering Derlin-1 engagement unknown
  19. 2023 Medium

    Extended FABP1 function to tumor-associated macrophages, where it interacts with PPARG/CD36 to drive fatty-acid oxidation and support HCC progression.

    Evidence Co-IP/Western blot, FABP1-KO TAM assays, FABP1-/- mouse HCC model, and mass cytometry

    PMID:38007237

    Open questions at the time
    • Direct vs indirect nature of PPARG/CD36 association not resolved
    • Reconciliation with PPARα-independent myeloid expression unaddressed
  20. 2024 Medium

    Showed FABP1 modulates CYP-mediated THC metabolism in an enzyme- and metabolite-specific manner, implicating it in drug-drug interactions.

    Evidence Reconstituted recombinant-CYP and human liver microsome metabolism assays with added purified FABP1 and LC-MS readout

    PMID:38583809

    Open questions at the time
    • Whether FABP1 physically contacts CYP enzymes not demonstrated
    • In vivo relevance to human cannabinoid pharmacokinetics untested

Open questions

Synthesis pass · forward-looking unresolved questions
  • The structural basis and triggering signal for FABP1 nuclear translocation and ligand handoff to PPARα, and how cytosolic, peroxisomal, and enzyme-coupled pools of FABP1 are partitioned and coordinated, remain unresolved.
  • No structure of the FABP1-PPARα complex
  • Mechanism of FABP1 nuclear import unknown
  • Coordination between cytosolic and peroxisomal pools undefined

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0008289 lipid binding 5 GO:0140104 molecular carrier activity 5 GO:0140110 transcription regulator activity 4 GO:0098772 molecular function regulator activity 3 GO:0016209 antioxidant activity 2
Localization
GO:0005634 nucleus 3 GO:0005829 cytosol 2 GO:0005777 peroxisome 1
Pathway
R-HSA-1430728 Metabolism 4 R-HSA-162582 Signal Transduction 3 R-HSA-9612973 Autophagy 1
Partners
AGR2CD36DERL1PPARAPPARGTRIM25UIS3VEGFR2

Evidence

Reading pass · 34 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2009 L-FABP directly binds PPARα protein with high affinity (Kd ~156 nM) and at close intermolecular distance (~52 Å), as demonstrated by co-immunoprecipitation of pure proteins, altered circular dichroic and fluorescence spectra, in vitro FRET between Cy3-labeled PPARα and Cy5-labeled L-FABP, co-IP from liver homogenates of wild-type mice, and double immunogold electron microscopy/FRET confocal microscopy in cultured primary hepatocytes. Co-IP of pure proteins, FRET (in vitro and confocal), circular dichroism, immunogold electron microscopy, co-IP from tissue Journal of lipid research High 19289416
2009 L-FABP gene ablation in primary hepatocytes reduces nuclear distribution of long-chain fatty acids, decreases PPARα co-immunoprecipitation with coactivator SRC-1 (with increased co-IP with co-inhibitor N-CoR), reduces palmitic acid-induced PPARα transcriptional activity, and decreases oxidation of palmitic acid, supporting a role for L-FABP in facilitating LCFA ligand delivery to nuclear PPARα. L-FABP knockout mouse primary hepatocytes, real-time laser scanning confocal imaging, co-immunoprecipitation, fatty acid oxidation assay Archives of biochemistry and biophysics High 19285478
2005 L-FABP gene ablation in male mice increases total bile acid pool size and alters expression of hepatic bile acid synthetic enzymes (CYP7A1, CYP27A1), bile acid transporters (BSEP, MRP2, OATP-1), cytosolic bile acid-binding proteins (GST, 3α-HSD), and nuclear receptors (LXRα, SHP), establishing L-FABP as a physiological regulator of hepatic bile acid and biliary cholesterol metabolism. L-FABP gene-ablated (knockout) mice, biochemical quantification of bile acid pools, Western blotting, gene expression analysis The Biochemical journal High 15984932
1998 Expression of L-FABP in L-cell fibroblasts increases fatty acid (NBD-stearate) uptake 1.7-fold, increases cytoplasmic diffusion rate of internalized fatty acid 1.9-fold, and increases lateral membrane mobility of NBD-stearate, demonstrating that L-FABP facilitates both cellular fatty acid uptake and intracellular trafficking. Stable transfection of L-cell fibroblasts with L-FABP cDNA, fluorescence digital imaging, single-cell fluorescence uptake assay The American journal of physiology Medium 9688651
1993 High-level expression of L-FABP in transfected L-cells stimulates both fatty acid (cis-parinaric acid) uptake and cholesterol uptake, and accelerates microsomal ACAT activity following sphingomyelinase-induced cholesterol redistribution, demonstrating that cytosolic L-FABP levels regulate both the extent and specificity of fatty acid and cholesterol absorption in intact cells. Stable transfection of L-cells with L-FABP cDNA, fluorescent fatty acid/cholesterol uptake assays, ACAT activity assay Molecular and cellular biochemistry Medium 8232270
2005 Circulating L-FABP is filtered by glomeruli and taken up by proximal tubule cells via megalin (LRP2)-mediated endocytosis. Quartz-crystal microbalance analysis showed Ca2+-dependent binding of L-FABP to megalin; degradation assays in megalin-expressing L2 cells confirmed megalin-mediated uptake and catabolism of 125I-L-FABP. In vivo 35S-L-FABP injection in rats with histoautoradiography, quartz-crystal microbalance binding assay, 125I-L-FABP degradation assay in megalin-expressing cells, immunohistochemistry Laboratory investigation High 15696188
2005 L-FABP expression in Chang liver cells reduces intracellular reactive oxygen species (ROS) under H2O2 and hypoxia/reoxygenation conditions, and decreases LDH release, demonstrating a direct antioxidative/cytoprotective function of L-FABP. Stable transfection of Chang liver cells with L-FABP cDNA, DCF fluorescence assay for ROS, LDH release assay Hepatology Medium 16175609
2006 A significant portion of cellular L-FABP localizes to the matrix of peroxisomes as a soluble protein, as demonstrated by analytical subcellular fractionation, 2D gel electrophoresis/MS of peroxisomal matrix proteins, and immunoelectron microscopy. Intraperoxisomal L-FABP was induced by clofibrate, and stimulated peroxisomal β-oxidation of palmitoyl-CoA and acyl-CoA thioesterase activity. Analytical subcellular fractionation, 2D gel electrophoresis and mass spectrometry, immunoelectron microscopy, in vitro peroxisomal β-oxidation assay The Biochemical journal High 16262600
2007 L-FABP directly interacts with the malaria parasite liver-stage protein UIS3, as identified by yeast two-hybrid screen and confirmed by yeast overexpression. Knockdown of L-FABP in hepatocytes severely impairs Plasmodium parasite growth; overexpression promotes growth, establishing L-FABP as a critical host factor for malaria liver stage development. Yeast two-hybrid screen, yeast overexpression, L-FABP knockdown in hepatocytes with parasite growth assay International journal for parasitology Medium 17303141
2012 4-Hydroxynonenal (4-HNE) modifies L-FABP at specific residues (Lys6, Lys31, His43, Lys46, Lys57, Cys69 in holo form; Lys57 and Cys69 in apo form) as mapped by MALDI-TOF/TOF MS. 4-HNE adduction reduces L-FABP ligand binding affinity and capacity (~50% reduction), decreases thermal stability (ΔTm=5.44°C), and alters the internal binding pocket geometry in molecular modeling. MALDI-TOF/TOF mass spectrometry, fluorescent ligand binding assay, thermal stability assay, computational molecular modeling PloS one Medium 22701647
2016 FABP1 binds endocannabinoids (AEA, 2-AG) and phytocannabinoids with high affinity as shown by fluorescent ligand displacement and intrinsic tyrosine fluorescence quenching assays. FABP1 gene ablation in mice significantly increases hepatic levels of AEA, 2-AG, and 2-OG, without changes in EC synthetic enzyme levels, identifying FABP1 as the major hepatic endocannabinoid binding and transport protein. Fluorescent ligand displacement assay, intrinsic fluorescence quenching, LC-MS quantification of endocannabinoids in FABP1-KO vs WT liver Biochemistry High 27552286
2019 FABP1 accommodates one molecule of Δ9-THC within its ligand binding pocket (determined by X-ray crystallography and molecular modeling). FABP1-knockout primary hepatocytes show reduced biotransformation of THC, and FABP1-KO mice exhibit reduced rates of THC biotransformation and potentiated pharmacodynamic/behavioral effects of THC, establishing FABP1 as a hepatic THC transport protein required for cannabinoid inactivation. X-ray crystallography, molecular modeling, in vitro binding assays, primary hepatocyte THC metabolism assay (FABP1-KO vs WT), pharmacokinetic/pharmacodynamic analysis in KO mice Scientific reports High 31110286
2018 FABP1 binds Δ9-THC and its metabolites (Δ9-THC-OH, Δ9-THC-COOH, Δ9-THC-CO-glucuronide) and differentially alters FABP1 secondary structure upon binding (circular dichroism). Fabp1 gene ablation dramatically increases hepatocyte accumulation of Δ9-THC and its metabolites and increases Δ9-THC-induced transcription of genes in endocannabinoid and lipid metabolism pathways. NBD-AEA fluorescence displacement assay, circular dichroism, primary hepatocyte culture with Fabp1 KO, LC-MS for metabolite quantification, rtPCR and Western blotting Biochemistry High 30232874
2012 FABP1 gene ablation increases LCFA β-oxidative enzyme expression and activity in a PPARα- and L-FABP-dependent manner: PUFA-mediated induction of PPARα-regulated β-oxidative enzymes (CPT1A, CPT2, ACOX1) is abolished in L-FABP-null or PPARα-null hepatocytes, and L-FABP redistributes to nuclei upon PUFA stimulation, augmented by high glucose. This establishes L-FABP as required for PUFA-mediated nuclear PPARα activation. Primary hepatocytes from WT, L-FABP-null, and PPARα-null mice, PPARα transcription assays, real-time confocal imaging, L-FABP/PPARα co-IP, β-oxidation assays American journal of physiology. Gastrointestinal and liver physiology High 23238934
2013 Fibrate-mediated PPARα transcriptional activation of LCFA β-oxidative genes requires L-FABP: L-FABP binds fibrates (bezafibrate, fenofibrate) and redistributes to nuclei upon fibrate treatment; this redistribution and PPARα activation are abolished in L-FABP-null, PPARα-null, or PPARα-inhibitor-treated hepatocytes. High glucose potentiates this fibrate-L-FABP-PPARα signaling. Primary hepatocytes from WT, L-FABP-null, PPARα-null mice, PPARα transcription assays, confocal nuclear redistribution imaging Biochimica et biophysica acta High 23747828
2014 FABP1 T94A variant protein has markedly altered secondary structural response to long-chain fatty acid binding (without significant change in fatty acid binding affinity), and markedly decreases PPARα-regulated β-oxidative enzyme induction by PUFAs (EPA, DHA) in primary human hepatocytes, establishing the T94A substitution as an altered/reduced function mutation affecting FABP1-PPARα signaling. In vitro fluorescence binding assays with recombinant human WT and T94A FABP1, circular dichroism, primary human hepatocyte cultures (TT, TC, CC genotypes), mRNA/protein expression The FEBS journal High 24628888
2010 The L-FABP T94A variant decreases free fatty acid uptake and alters intracellular lipid partitioning (decreased triglyceride, increased cholesterol) in stably transfected Chang liver cells, demonstrating the functional consequence of this SNP on hepatic fatty acid metabolism. Site-directed mutagenesis, stable transfection of Chang liver cells, radiotracer FFA uptake/efflux assays, lipid quantification Molecular and cellular biochemistry Medium 20721681
2015 Human FABP1 T94A variant protein has ~3-fold higher cholesterol-binding affinity than WT FABP1 T94T (by NBD-cholesterol fluorescence assay and isothermal titration calorimetry), and primary human hepatocytes expressing T94A show faster HDL- and LDL-mediated cholesterol uptake, identifying enhanced cholesterol binding as a functional consequence of this variant. Fluorescence NBD-cholesterol binding assay, isothermal titration calorimetry, primary human hepatocyte cholesterol uptake assays (TT vs CC genotyped donors) Biochimica et biophysica acta High 25732850
2014 In primary hepatocytes from FABP1 T94A variant (CC genotype) female donors, TG accumulation occurs via increased lipogenesis pathway gene expression (GPAM, LPIN2), decreased LCFA β-oxidation, and impaired fenofibrate-mediated FABP1 nuclear redistribution and PPARα transcriptional activity, despite increased total FABP1 protein levels. Primary human hepatocyte cultures from genotyped donors (TT vs TC vs CC), lipid quantification, mRNA/protein expression, β-oxidation assay, confocal imaging American journal of physiology. Gastrointestinal and liver physiology High 24875102
2018 FABP1 considerably enhances monoacylglycerol lipase-mediated hydrolysis of 2-AG in vitro; Fabp1 gene ablation markedly diminishes 2-AG hydrolysis in hepatocytes. FABP1 binds ARA (2:1 stoichiometry) but 2-AG and AEA (1:1 stoichiometry, apparently at different sites). Loss of FABP1 enhances AEA uptake but has little effect on 2-AG uptake, revealing differential roles in endocannabinoid intracellular targeting and degradation. In vitro MAGL/FAAH hydrolysis assays with recombinant FABP1, LC-MS for hepatocyte EC levels in LKO vs WT, real-time imaging with fluorescent NBD-labeled EC probes, fluorescence binding assays Lipids High 30203570
2013 L-Fabp deletion in hepatic stellate cells (HSCs) reduces lipid droplet abundance and promotes activation-related gene expression. Adenoviral L-Fabp transduction inhibits activation of passaged HSCs and increases prolipogenic gene expression and intracellular lipid (TG and palmitate) accumulation, establishing L-FABP as a modulator of HSC activation and lipid storage in the fibrogenic program. L-FABP KO primary HSC isolation, adenoviral transduction, gene expression analysis, lipid/FA quantification, in vivo high-fat diet feeding model Hepatology Medium 23401290
2014 Hepatic ATGL-mediated fatty acid channeling to β-oxidation and PPARα activation does not require L-FABP: L-FABP deletion did not impair ATGL overexpression effects on hydrolyzed FA oxidation in primary hepatocytes or on PPARα target gene expression in vivo, establishing that ATGL signals through an L-FABP-independent mechanism. Adenovirus-mediated ATGL knockdown/overexpression in WT and L-FABP KO mice, primary hepatocyte oxidation assays, serum β-hydroxybutyrate measurement, PPARα target gene expression Journal of lipid research Medium 24610891
2012 L-FABP knockout mice exhibit higher sustained oxidative stress (elevated glutathione depletion, TBARS, 8-isoprostanes, protein carbonyl content, HNE/MDA adducts) during ethanol feeding compared to WT, establishing that L-FABP functions as an indirect antioxidant protein essential for sequestering free fatty acids and limiting lipid peroxidation. L-FABP KO mice fed ethanol (Lieber-DeCarli diet), biochemical oxidative stress markers, lipidomics, immunohistochemistry Journal of lipid research Medium 23359610
2016 L-FABP is exclusively expressed within the myeloid lineage in murine alveolar macrophages (not in other macrophage subtypes or dendritic cells), confirmed by real-time PCR and double immunofluorescence. L-FABP expression in alveolar macrophages is independent of PPARα (PPARα mRNA is absent in these cells despite L-FABP expression), suggesting an alternative transcriptional mechanism. Real-time PCR, immunofluorescence/double fluorescence analysis of myeloid lineage cells The international journal of biochemistry & cell biology Medium 15203117
2013 FOXA1 and PPARα are major transcriptional activators of human FABP1, while C/EBPα is a dominant repressor. Reporter assays localized the major basal FABP1 promoter activity to -96 to -229 bp with a DR1-C/EBP composite element at -123 bp; C/EBPα binds this element to displace HNF4α. HNF4α gene silencing reduces FABP1 mRNA. PPARα operates through a conserved proximal element at -59 bp. Adenovirus-mediated TF expression in HepG2 cells and primary human hepatocytes, reporter assays, site-directed mutagenesis of promoter elements, shRNA gene silencing Biochimica et biophysica acta High 23318274
2016 L-FABP associates with VEGFR2 on membrane rafts in HCC cells and subsequently activates Akt/mTOR/P70S6K/4EBP1 and Src/FAK/cdc42 signaling pathways, upregulates VEGF-A, and increases angiogenic potential and cell migration. Co-immunoprecipitation of L-FABP with VEGFR2, pathway inhibitor assays, xenograft mouse model, VEGF-A expression analysis Oncotarget Medium 26919097
2023 FABP1 interacts with PPARG/CD36 in tumor-associated macrophages (TAMs) to increase fatty acid oxidation, as demonstrated by Western blot and co-immunoprecipitation. FABP1 deficiency in TAMs inhibits HCC progression in vitro, and FABP1-KO mice show attenuated tumor growth with altered immune cell composition. Co-immunoprecipitation, Western blot, in vitro FABP1 KO TAM assays, in vivo FABP1-/- mouse HCC model, mass cytometry Journal for immunotherapy of cancer Medium 38007237
2017 FABP1 knockdown in Caco-2 enterocytes reduces initial oleate uptake rate, long-term oleate incorporation, basolateral oleate secretion, and enterocyte proliferation rate, demonstrating that FABP1 is required for proper intestinal fatty acid uptake, transcellular transport, and cell proliferation. Stable antisense cDNA transfection (FABP1as) in Caco-2 cells, radiotracer oleate uptake assays, lipid quantification, proliferation assay Biochimica et biophysica acta. Molecular and cell biology of lipids Medium 28919479
2014 L-FABP ablation in bile acid/cholesterol studies: LKO markedly decreases hepatic bile acid concentration and alters biliary bile acid composition toward higher hydrophobicity; LKO also decreases hepatic uptake and biliary secretion of HDL-derived cholesterol, while SCP-2/SCP-x ablation alone does not affect hepatic bile acid concentration, suggesting distinct and complementary roles for the two proteins. L-FABP KO, SCP-2/SCP-x KO, and triple-KO male mice; hepatic and biliary bile acid/cholesterol quantification; NBD-cholesterol uptake assay American journal of physiology. Gastrointestinal and liver physiology Medium 25277800
2019 FABP1 overexpression in the mouse liver inhibits autophagic flux by blocking lysosomal function (lysosomal proteolysis and acidification), and this inhibition of autophagy-lysosomal machinery contributes to hepatic steatosis; exercise-induced reduction of FABP1 restores autophagic flux and alleviates steatosis. Adenoviral liver-specific FABP1 overexpression in mice, autophagic flux assays, lysosomal function assays, quantitative proteomics FASEB journal Medium 31366243
2023 Derlin-1 physically interacts with FABP1 and promotes its ubiquitylation and proteasomal degradation. The E3 ubiquitin ligase Trim25 is recruited to the complex to promote FABP1 polyubiquitylation. Derlin-1 overexpression reduces FABP1 levels and lipid deposition in a FABP1-dependent manner in HepG2 cells and mice. Co-immunoprecipitation (liver tissue and cell lines), mass spectrometry, adenovirus-mediated Derlin-1 overexpression in mice, FABP1 ubiquitination assays Free radical biology & medicine Medium 37499886
2021 Anterior gradient 2 (AGR2) physically interacts with FABP1 via a PDI motif forming a disulfide bond, stabilizes FABP1 protein, and thereby facilitates long-chain fatty acid uptake and lipid accumulation; AGR2 overexpression without PDI activity fails to suppress lipid accumulation in FABP1-null cells, establishing the interaction as functionally required. Co-immunoprecipitation, proteomic analysis of AGR2-KO liver, mutagenesis of AGR2 PDI motif, FABP1 stability assay, KO and overexpression mouse models International journal of biological sciences Medium 33767592
2020 The RNA-binding protein DDX5 binds Fabp1 mRNA and augments its expression post-transcriptionally. DDX5 knockout in intestinal epithelial cells reduces FABP1 protein and protects mice from intestinal tumorigenesis, placing DDX5 as an upstream post-transcriptional regulator of FABP1. RNA-binding protein pulldown (DDX5 binds Fabp1 mRNA), DDX5 KO in epithelial cells, intestinal tumorigenesis model Life science alliance Medium 32817263
2024 FABP1 alters CYP-mediated THC metabolism in an enzyme- and metabolite-specific manner: FABP1 binding to THC changes the fraction metabolized by CYP2C9, CYP2C19, and CYP3A4/5 in both recombinant CYP and human liver microsome assays, suggesting that FABP1 may interact with CYP enzymes and serve as a site of drug-drug interactions. In vitro metabolism assays with recombinant CYPs and human liver microsomes (HLMs), addition of purified FABP1 protein, metabolite quantification by LC-MS Biochemical pharmacology Medium 38583809

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2005 Antioxidative function of L-FABP in L-FABP stably transfected Chang liver cells. Hepatology (Baltimore, Md.) 133 16175609
2009 L-FABP directly interacts with PPARalpha in cultured primary hepatocytes. Journal of lipid research 129 19289416
2015 L-FABP: A novel biomarker of kidney disease. Clinica chimica acta; international journal of clinical chemistry 108 25797895
2013 The human liver fatty acid binding protein (FABP1) gene is activated by FOXA1 and PPARα; and repressed by C/EBPα: Implications in FABP1 down-regulation in nonalcoholic fatty liver disease. Biochimica et biophysica acta 89 23318274
2017 Silencing of FABP1 ameliorates hepatic steatosis, inflammation, and oxidative stress in mice with nonalcoholic fatty liver disease. FEBS open bio 85 28680813
2014 Association of urinary KIM-1, L-FABP, NAG and NGAL with incident end-stage renal disease and mortality in American Indians with type 2 diabetes mellitus. Diabetologia 83 25316431
2007 L-FABP is a critical host factor for successful malaria liver stage development. International journal for parasitology 82 17303141
2013 Liver fatty acid binding protein (L-Fabp) modulates murine stellate cell activation and diet-induced nonalcoholic fatty liver disease. Hepatology (Baltimore, Md.) 77 23401290
2013 Gut-associated biomarkers L-FABP, I-FABP, and TFF3 and LIT score for diagnosis of surgical necrotizing enterocolitis in preterm infants. Annals of surgery 71 23470582
2005 Evidence for megalin-mediated proximal tubular uptake of L-FABP, a carrier of potentially nephrotoxic molecules. Laboratory investigation; a journal of technical methods and pathology 70 15696188
1998 L-FABP and I-FABP expression increase NBD-stearate uptake and cytoplasmic diffusion in L cells. The American journal of physiology 63 9688651
2011 Renal liver-type fatty acid binding protein (L-FABP) attenuates acute kidney injury in aristolochic acid nephrotoxicity. The American journal of pathology 61 21356355
2007 Diet-induced obesity and hepatic steatosis in L-Fabp / mice is abrogated with SF, but not PUFA, feeding and attenuated after cholesterol supplementation. American journal of physiology. Gastrointestinal and liver physiology 60 18032478
2005 Liver fatty-acid-binding protein (L-FABP) gene ablation alters liver bile acid metabolism in male mice. The Biochemical journal 60 15984932
2014 Urinary KIM-1, NGAL and L-FABP for the diagnosis of AKI in patients with acute coronary syndrome or heart failure undergoing coronary angiography. Heart and vessels 59 24989970
2003 435-bp liver regulatory sequence in the liver fatty acid binding protein (L-FABP) gene is sufficient to modulate liver regional expression in transgenic zebrafish. Developmental dynamics : an official publication of the American Association of Anatomists 59 12815620
2022 Downregulation of PPARα mediates FABP1 expression, contributing to IgA nephropathy by stimulating ferroptosis in human mesangial cells. International journal of biological sciences 57 36147466
2020 FABP1 and FABP2 as markers of diabetic nephropathy. International journal of medical sciences 56 32922199
1993 Expression of rat L-FABP in mouse fibroblasts: role in fat absorption. Molecular and cellular biochemistry 56 8232270
2019 Long-term exercise prevents hepatic steatosis: a novel role of FABP1 in regulation of autophagy-lysosomal machinery. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 54 31366243
2017 Elevated FABP1 serum levels are associated with poorer survival in acetaminophen-induced acute liver failure. Hepatology (Baltimore, Md.) 53 27859489
2012 Two genetic variants in FABP1 and susceptibility to non-alcohol fatty liver disease in a Chinese population. Gene 53 22465531
2012 Characterization of 4-HNE modified L-FABP reveals alterations in structural and functional dynamics. PloS one 53 22701647
2012 Urinary L-FABP and its combination with urinary NGAL in early diagnosis of acute kidney injury after cardiac surgery in adult patients. Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals 53 23167703
2016 Liver fatty acid-binding protein (L-FABP) promotes cellular angiogenesis and migration in hepatocellular carcinoma. Oncotarget 52 26919097
2013 Clinical value of NGAL, L-FABP and albuminuria in predicting GFR decline in type 2 diabetes mellitus patients. PloS one 52 23349979
2016 FABP1: A Novel Hepatic Endocannabinoid and Cannabinoid Binding Protein. Biochemistry 51 27552286
2009 NGAL (neutrophil gelatinase-associated lipocalin) and L-FABP after percutaneous coronary interventions due to unstable angina in patients with normal serum creatinine. Advances in medical sciences 48 19875355
2023 Single-cell RNA-sequencing atlas reveals an FABP1-dependent immunosuppressive environment in hepatocellular carcinoma. Journal for immunotherapy of cancer 46 38007237
2017 FABP1 knockdown in human enterocytes impairs proliferation and alters lipid metabolism. Biochimica et biophysica acta. Molecular and cell biology of lipids 46 28919479
2009 Liver type fatty acid binding protein (L-FABP) gene ablation reduces nuclear ligand distribution and peroxisome proliferator-activated receptor-alpha activity in cultured primary hepatocytes. Archives of biochemistry and biophysics 46 19285478
2016 Fatty Acid Binding Protein-1 (FABP1) and the Human FABP1 T94A Variant: Roles in the Endocannabinoid System and Dyslipidemias. Lipids 44 27117865
2012 Impact of L-FABP and glucose on polyunsaturated fatty acid induction of PPARα-regulated β-oxidative enzymes. American journal of physiology. Gastrointestinal and liver physiology 43 23238934
2020 Circulating fatty acid-binding protein 1 (FABP1) and nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. International journal of medical sciences 42 32038102
2014 NGAL, L-FABP, and KIM-1 in comparison to established markers of renal dysfunction. Clinical chemistry and laboratory medicine 41 24243749
2009 Urinary L-FABP and anaemia: distinct roles of urinary markers in type 2 diabetes. European journal of clinical investigation 41 19912308
2020 Urinary I-FABP, L-FABP, TFF-3, and SAA Can Diagnose and Predict the Disease Course in Necrotizing Enterocolitis at the Early Stage of Disease. Journal of immunology research 39 32190704
2015 Role of new biomarkers for predicting renal scarring in vesicoureteral reflux: NGAL, KIM-1, and L-FABP. Pediatric nephrology (Berlin, Germany) 39 26324091
2014 Hepatic ATGL mediates PPAR-α signaling and fatty acid channeling through an L-FABP independent mechanism. Journal of lipid research 39 24610891
2013 Susceptibility of L-FABP-/- mice to oxidative stress in early-stage alcoholic liver. Journal of lipid research 38 23359610
2022 Exendin-4 alleviates steatosis in an in vitro cell model by lowering FABP1 and FOXA1 expression via the Wnt/-catenin signaling pathway. Scientific reports 37 35140289
2006 Localization of a portion of the liver isoform of fatty-acid-binding protein (L-FABP) to peroxisomes. The Biochemical journal 37 16262600
2013 Inhibitors of Fatty Acid Synthesis Induce PPAR α -Regulated Fatty Acid β -Oxidative Genes: Synergistic Roles of L-FABP and Glucose. PPAR research 36 23533380
2012 Decreased body weight and hepatic steatosis with altered fatty acid ethanolamide metabolism in aged L-Fabp -/- mice. Journal of lipid research 36 22327204
2014 Structural and functional interaction of fatty acids with human liver fatty acid-binding protein (L-FABP) T94A variant. The FEBS journal 35 24628888
2014 Performance of urinary NGAL and L-FABP in predicting acute kidney injury and subsequent renal recovery: a cohort study based on major surgeries. Clinical chemistry and laboratory medicine 32 24293449
2015 Loss of L-FABP, SCP-2/SCP-x, or both induces hepatic lipid accumulation in female mice. Archives of biochemistry and biophysics 31 26116377
2014 Human FABP1 T94A variant impacts fatty acid metabolism and PPAR-α activation in cultured human female hepatocytes. American journal of physiology. Gastrointestinal and liver physiology 31 24875102
2010 L-FABP T94A decreased fatty acid uptake and altered hepatic triglyceride and cholesterol accumulation in Chang liver cells stably transfected with L-FABP. Molecular and cellular biochemistry 30 20721681
2016 Elevated levels of circulating CDH5 and FABP1 in association with human drug-induced liver injury. Liver international : official journal of the International Association for the Study of the Liver 29 27224670
2014 Non-inferiority of creatinine excretion rate to urinary L-FABP and NGAL as predictors of early renal allograft function. BMC nephrology 28 25027586
2013 High glucose potentiates L-FABP mediated fibrate induction of PPARα in mouse hepatocytes. Biochimica et biophysica acta 28 23747828
2004 L-FABP is exclusively expressed in alveolar macrophages within the myeloid lineage: evidence for a PPARalpha-independent expression. The international journal of biochemistry & cell biology 28 15203117
2016 FABP-1 gene ablation impacts brain endocannabinoid system in male mice. Journal of neurochemistry 26 27167970
2016 Subfunctionalization of peroxisome proliferator response elements accounts for retention of duplicated fabp1 genes in zebrafish. BMC evolutionary biology 26 27421266
2011 Protective effects of L-type fatty acid-binding protein (L-FABP) in proximal tubular cells against glomerular injury in anti-GBM antibody-mediated glomerulonephritis. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 25 21525165
2020 DDX5 promotes oncogene C3 and FABP1 expressions and drives intestinal inflammation and tumorigenesis. Life science alliance 24 32817263
2020 Evaluation of urinary L-FABP as an early marker for diabetic nephropathy in type 2 diabetic patients. Journal of medical biochemistry 24 33033456
2019 FABP1 controls hepatic transport and biotransformation of Δ9-THC. Scientific reports 24 31110286
2015 Cold stress initiates the Nrf2/UGT1A1/L-FABP signaling pathway in chickens. Poultry science 23 26453599
2023 Discovery of the First-in-Class Intestinal Restricted FXR and FABP1 Dual Modulator ZLY28 for the Treatment of Nonalcoholic Fatty Liver Disease. Journal of medicinal chemistry 22 37079895
2016 Fabp1 gene ablation inhibits high-fat diet-induced increase in brain endocannabinoids. Journal of neurochemistry 22 27861894
2015 Human FABP1 T94A variant enhances cholesterol uptake. Biochimica et biophysica acta 22 25732850
2013 Liver fatty acid-binding protein (L-Fabp) modifies intestinal fatty acid composition and adenoma formation in ApcMin/+ mice. Cancer prevention research (Philadelphia, Pa.) 21 23921281
2013 [Urinary L-type fatty acid binding protein (L-FABP) as a new urinary biomarker promulgated by the Ministry of Health, Labour and Welfare in Japan]. Rinsho byori. The Japanese journal of clinical pathology 20 24205707
2011 Analysis for the combination expression of CK20, FABP1 and MUC2 is sensitive for the prediction of peritoneal recurrence in gastric cancer. Japanese journal of clinical oncology 20 22172348
2010 Comparative effects of benidipine and amlodipine on proteinuria, urinary 8-OHdG, urinary L-FABP, and inflammatory and atherosclerosis markers in early-stage chronic kidney disease. The American journal of the medical sciences 20 20145433
2007 Decreased expression of Intestinal I- and L-FABP levels in rare human genetic lipid malabsorption syndromes. Histochemistry and cell biology 20 17605029
2022 FABP1 expression in human tumors: a tissue microarray study on 17,071 tumors. Virchows Archiv : an international journal of pathology 19 35951102
2021 The Involvement of TRIB3 and FABP1 and Their Potential Functions in the Dynamic Process of Gastric Cancer. Frontiers in molecular biosciences 19 34957220
2017 Association of IL-1β, IL-1Ra and FABP1 gene polymorphisms with the metabolic features of polycystic ovary syndrome. Inflammation research : official journal of the European Histamine Research Society ... [et al.] 19 28405733
2021 Mechanistic Investigation on the Regulation of FABP1 by the IL-6/miR-603 Signaling in the Pathogenesis of Hepatocellular Carcinoma. BioMed research international 18 34056002
2021 Quantitative Chemical Proteomics Reveals Interspecies Variations on Binding Schemes of L-FABP with Perfluorooctanesulfonate. Environmental science & technology 17 34133149
2017 Multiple MicroRNAs Ameliorate Hepatocyte Steatosis and Injury by Suppressing FABP1 Expression. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 17 29258109
2015 Phenotypic divergence in two lines of L-Fabp-/- mice reflects substrain differences and environmental modifiers. American journal of physiology. Gastrointestinal and liver physiology 17 26251469
2015 Association of a Human FABP1 Gene Promoter Region Polymorphism with Altered Serum Triglyceride Levels. PloS one 17 26439934
2011 Computational prediction and experimental validation associating FABP-1 and pancreatic adenocarcinoma with diabetes. BMC gastroenterology 17 21251264
1993 Linkage of the murine transforming growth factor alpha gene with Igk, Ly-2, and Fabp1 on chromosome 6. Genomics 17 8100806
2024 CYP2C9, CYP3A and CYP2C19 metabolize Δ9-tetrahydrocannabinol to multiple metabolites but metabolism is affected by human liver fatty acid binding protein (FABP1). Biochemical pharmacology 16 38583809
2019 Clinical significance of urinary L-FABP in the emergency department. International journal of emergency medicine 16 31470789
2016 Female Mice are Resistant to Fabp1 Gene Ablation-Induced Alterations in Brain Endocannabinoid Levels. Lipids 16 27450559
2014 Evaluation of the expression of I-FABP and L-FABP in a necrotizing enterocolitis model after the use of Lactobacillus acidophilus. Journal of pediatric surgery 16 25840060
2013 L-FABP can be an early marker of acute kidney injury in children. Pediatric nephrology (Berlin, Germany) 16 23407997
2019 Effect of liver fatty acid binding protein (L-FABP) gene ablation on lipid metabolism in high glucose diet (HGD) pair-fed mice. Biochimica et biophysica acta. Molecular and cell biology of lipids 15 30910689
2014 Ablating L-FABP in SCP-2/SCP-x null mice impairs bile acid metabolism and biliary HDL-cholesterol secretion. American journal of physiology. Gastrointestinal and liver physiology 15 25277800
2012 Expression pattern of L-FABP gene in different tissues and its regulation of fat metabolism-related genes in duck. Molecular biology reports 15 23065214
2021 The association between a Fatty Acid Binding Protein 1 (FABP1) gene polymorphism and serum lipid abnormalities in the MASHAD cohort study. Prostaglandins, leukotrienes, and essential fatty acids 13 34418801
2021 Decreased Fatty Acid Transporter FABP1 and Increased Isoprostanes and Neuroprostanes in the Human Term Placenta: Implications for Inflammation and Birth Weight in Maternal Pre-Gestational Obesity. Nutrients 13 34444927
2016 Impact of dietary phytol on lipid metabolism in SCP2/SCPX/L-FABP null mice. Biochimica et biophysica acta. Molecular and cell biology of lipids 13 27940000
2023 Echinocystic acid prevents obesity and fatty liver via interacting with FABP1. Phytotherapy research : PTR 12 37092723
2023 Derlin-1 ameliorates nonalcoholic hepatic steatosis by promoting ubiquitylation and degradation of FABP1. Free radical biology & medicine 12 37499886
2018 Impact of Fabp1 Gene Ablation on Uptake and Degradation of Endocannabinoids in Mouse Hepatocytes. Lipids 12 30203570
2004 Effect of dexamethasone, 2-bromopalmitate and clofibrate on L-FABP mediated hepatoma proliferation. The Journal of pharmacy and pharmacology 12 15324484
2023 Hepatotoxicity assessment investigations on PFASs targeting L-FABP using binding affinity data and machine learning-based QSAR model. Ecotoxicology and environmental safety 11 37523843
2023 Disclosing Environmental Ligands of L-FABP and PPARγ: Should We Re-evaluate the Chemical Safety of Hydrocarbon Surfactants? Environmental science & technology 11 37527448
2021 Anterior gradient 2 increases long-chain fatty acid uptake via stabilizing FABP1 and facilitates lipid accumulation. International journal of biological sciences 11 33767592
2021 Rapid and sensitive detection of L-FABP for prediction and diagnosis of acute kidney injury in critically ill patients by chemiluminescent immunoassay. Journal of clinical laboratory analysis 11 34651352
2018 Δ9-Tetrahydrocannabinol induces endocannabinoid accumulation in mouse hepatocytes: antagonism by Fabp1 gene ablation. Journal of lipid research 11 29414765
2018 Structural and Functional Interaction of Δ9-Tetrahydrocannabinol with Liver Fatty Acid Binding Protein (FABP1). Biochemistry 11 30232874
2013 Differential expression of L-FABP and L-BABP between fat and lean chickens. Genetics and molecular research : GMR 11 24114214

Missed literature

Know a paper Affinage missed for FABP1? Flag it for the maintainers and the community.

No submissions yet.